1. Home
  2. INTS

INTS

Intensity Therapeutics Inc. Common stock

Logo Intensity Therapeutics Inc. Common stock

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Founded: 2012 Country:
United States
United States
Employees: N/A City: WESTPORT
Market Cap: 62.9M IPO Year: 2023
Target Price: $12.00 AVG Volume (30 days): 59.7K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.38 EPS Growth: N/A
52 Week Low/High: $2.01 - $11.44 Next Earning Date: 05-06-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: